Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded…
LOS ANGELES, May 26, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR…